Thymosin Alpha-1 Boosts Immune Cells and Reduces Tumor Growth and Spread in Mice
Daily thymosin alpha-1 injections increased immune cells, reduced tumor weight, and prevented organ metastasis in tumor-bearing mice in a dose-dependent manner.
Quick Facts
What This Study Found
Thymosin alpha-1 (0.01-10 μg SC daily for 7 days) increased thymocytes and blood cells, reduced primary tumor weight, and inhibited organ colonization by metastatic cells in tumor-bearing BALB/c mice.
Key Numbers
How They Did This
Animal study in BALB/c mice bearing tumors. Thymosin alpha-1 administered SC daily for 7 consecutive days at multiple doses. Immune cell counts, tumor weight, and metastatic organ colonization assessed.
Why This Research Matters
Thymosin alpha-1 is already used clinically as an immune enhancer. Demonstrating anti-tumor and anti-metastatic activity strengthens the case for its use as a cancer immunotherapy adjuvant.
The Bigger Picture
Cancer immunotherapy aims to boost the immune system to fight tumors. Thymosin alpha-1's ability to simultaneously enhance immune cells and reduce tumor growth and spread aligns perfectly with this therapeutic strategy.
What This Study Doesn't Tell Us
Mouse model with specific tumor type. Short 7-day treatment. Human cancer is more complex than murine models. The specific immune mechanisms driving tumor reduction were not fully characterized.
Questions This Raises
- ?Which immune cell populations are responsible for the anti-tumor effect?
- ?Does thymosin alpha-1 enhance responses to conventional chemotherapy?
- ?What is the optimal dosing schedule for anti-cancer effects?
Trust & Context
- Key Stat:
- Reduced tumor + metastasis 7 days of thymosin alpha-1 both reduced primary tumor weight and prevented cancer spread to other organs in mice
- Evidence Grade:
- Preliminary animal evidence with clear dose-dependent effects on immune cells, tumor weight, and metastasis.
- Study Age:
- Published in 2000. Thymosin alpha-1 has continued to be studied as a cancer immunotherapy adjuvant, with clinical trials in various cancers.
- Original Title:
- Thymosin alpha(1) application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice.
- Published In:
- Cancer letters, 159(1), 9-13 (2000)
- Authors:
- Beuth, J, Schierholz, J M, Mayer, G
- Database ID:
- RPEP-00579
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can thymosin alpha-1 fight cancer?
In this mouse study, it reduced tumor size and prevented cancer spread by boosting immune cells. Thymosin alpha-1 is being studied as an addition to standard cancer treatment to enhance the immune system's ability to fight tumors.
How does it work against cancer?
By increasing immune cell numbers and activity, thymosin alpha-1 helps the body recognize and attack cancer cells. It doesn't kill tumors directly — it empowers the immune system to do so.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00579APA
Beuth, J; Schierholz, J M; Mayer, G. (2000). Thymosin alpha(1) application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice.. Cancer letters, 159(1), 9-13.
MLA
Beuth, J, et al. "Thymosin alpha(1) application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice.." Cancer letters, 2000.
RethinkPeptides
RethinkPeptides Research Database. "Thymosin alpha(1) application augments immune response and d..." RPEP-00579. Retrieved from https://rethinkpeptides.com/research/beuth-2000-thymosin-alpha1-application-augments
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.